Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age-associated outcomes in cardiogenic shock supported with microaxial flow pumps.

Annals of intensive care·2026
Same author

cAMP production secondary to A<sub>2A</sub> adenosine receptor activation as a biomarker of ischemia-reperfusion process: A comparative pilot study between CABG and PCI.

International journal of cardiology·2026
Same author

Experts' recommendations for the management of adult patients with cardiogenic shock.

Annals of intensive care·2026
Same author

Bleeding and thrombotic events during micro-axial flow pump support: A European multicenter cohort study.

Critical care (London, England)·2026
Same author

Beyond the STEMI paradigm: Expanding the scope of microAxial flow pump in cardiogenic shock.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Experts' recommendations for the management of adult patients with cardiogenic shock.

Archives of cardiovascular diseases·2026

Related Experiment Video

Updated: May 28, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

High on treatment platelet reactivity.

Omar Ait-Mokhtar1, Laurent Bonello, Saida Benamara

  • 1Department of Cardiology, Centre Hospitalier Universitaire Nord, Marseille 13015, France. aitmokhtar1@yahoo.fr

Heart, Lung & Circulation
|October 18, 2011
PubMed
Summary

Dual antiplatelet therapy with aspirin and clopidogrel reduces cardiovascular events after percutaneous coronary intervention. However, high on-treatment platelet reactivity (HTPR) remains a concern, linked to ischemic events and stent thrombosis.

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Experiment Videos

Last Updated: May 28, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard after percutaneous coronary intervention (PCI).
  • Despite DAPT, ischemic events, including stent thrombosis, persist and are associated with high mortality.
  • Inter-individual variability in clopidogrel response leads to high on-treatment platelet reactivity (HTPR) in 4-46% of patients.

Purpose of the Study:

  • To summarize the current understanding of high on-treatment platelet reactivity (HTPR) in patients undergoing PCI.
  • To highlight the association between HTPR and adverse ischemic events post-PCI.
  • To address the ongoing debate regarding the routine assessment and clinical interpretation of platelet reactivity.

Main Methods:

  • Review of recent studies and clinical data.
  • Analysis of the relationship between clopidogrel response and ischemic events.
  • Discussion of the challenges in assessing and utilizing platelet reactivity measurements in clinical practice.

Main Results:

  • A significant association exists between HTPR and increased risk of ischemic events in PCI patients.
  • HTPR prevalence varies widely (4-46%), indicating substantial inter-individual differences in clopidogrel efficacy.
  • Current methods for assessing platelet reactivity and guiding treatment decisions remain controversial.

Conclusions:

  • HTPR is a significant clinical issue in patients treated with clopidogrel after PCI.
  • Further research and standardized guidelines are needed for effective management of HTPR.
  • Optimizing antiplatelet therapy based on individual response is crucial to reduce cardiovascular events and stent thrombosis.